Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

@article{Fong2009InhibitionOP,
  title={Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.},
  author={Peter C.C. Fong and David S. Boss and Timothy Anthony Yap and Andrew N. J. Tutt and Pei Jun Wu and Marja W. J. Mergui-Roelvink and Peter S. Mortimer and Helen C. Swaisland and Alan Lau and Mark J. O’Connor and Alan Ashworth and James Carmichael and Stanley B. Kaye and Jan H. M. Schellens and Johann S. de Bono},
  journal={The New England journal of medicine},
  year={2009},
  volume={361 2},
  pages={
          123-34
        }
}
BACKGROUND The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. METHODS This was a phase 1 trial that included the analysis of pharmacokinetic and pharmacodynamic… 

Tables from this paper

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  • P. FongT. Yap S. Kaye
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity, a significant association between the clinical benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups.

New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.

Despite the evidence of the synthetic lethal effects of PARPi, they are not always effective in HR defective cancers, and as they become part of standard of care in breast cancer, the study of prevalence of distinct mechanisms of resistance to PARPi and cross-resistance with other DNA-damaging agents such as platinum will be important and may inform therapy choices.

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer

Data from early clinical trials suggest a role in the treatment of BRCA-related and triple-negative breast cancer and a wider role for this class of drug in breast cancer is proposed; however, as little is known about the long-term effects of these drugs, this work should proceed with caution and await results of the ongoing clinical trials.

The clinical development of inhibitors of poly(ADP-ribose) polymerase.

  • H. CalvertA. Azzariti
  • Biology, Chemistry
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2011
PARP inhibitors were initially developed as possible chemo-potentiating agents but have now been evaluated clinically in BRCA-related tumors, showing remarkable single-agent activity.

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi), which result in synergistic antitumor effects when combined with cisplatin, temozolomide, topoisomerase inhibitors and ionizing radiation.

Current status of poly(ADP-ribose) polymerase inhibitors and future directions

Preclinical and clinical data for PARP inhibitors are summarized, their potential for future applications to treat various malignancies are discussed and potential long-term side effects and suitable biomarkers for predicting efficacy and mechanisms of clinical resistance are in discussion.

Poly(ADP-Ribose) Polymerase-1 Inhibition: Preclinical and Clinical Development of Synthetic Lethality

This new class of agents may offer more therapeutic specificity by exploiting a DNA repair defect seen in some human tumors with initial clinical trials demonstrating antitumor activity.
...

References

SHOWING 1-10 OF 35 REFERENCES

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

It is proposed that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair and exploited in order to kill BRCA2-deficient tumours by PARP inhibition alone.

Resistance to therapy caused by intragenic deletion in BRCA2

It is shown that resistance to PARP inhibition can be acquired by deletion of a mutation in BRCA2, and new BRCa2 isoforms were expressed in the resistant lines as a result of intragenic deletion of the c.6174delT mutation and restoration of the open reading frame (ORF).

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

The results indicate that PARP inhibition might be a useful therapeutic strategy not only for the treatment of BRCA mutation-associated tumors but also for a wider range of tumors bearing a variety of deficiencies in the HR pathway or displaying properties of 'BRCAness.

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  • A. Ashworth
  • Biology, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCa2, are highly sensitive to blockade of the repair of DNA single-Strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase, providing the basis for a novel synthetic lethal approach to cancer therapy.

Selective Inhibition of BRCA 2-Deficient MammaryTumor Cell Growth byAZD 2281 and Cisplatin

The first set of BRCA2-deficient mammary tumor cell lines are established, which form an important addition to the existing preclinical models for B RCA-mutated breast cancer and provide strong support for AZD2281, alone or in combination with cisplatin, as a novel targeted therapeutic against BRCa- deficient cancers.

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

The exquisite sensitivity of these cells to the PARP inhibitor AZD 2281, alone or in combination with cisplatin, provides strong support for AZD2281 as a novel targeted therapeutic against BRCA-deficient cancers.

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

The results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

These efforts are described, based on understanding the DNA repair defects in BRCAdeficient cells, to define the optimal existing treatment for cancers arising from BRCA mutation carriers and the development of novel therapeutic approaches.

The PARP superfamily

This review summarizes the present knowledge of this emerging superfamily of Poly(ADP‐ribose) polymerases, which might ultimately improve pharmacological strategies to enhance both antitumor efficacy and the treatment of a number of inflammatory and neurodegenerative disorders.